Aubrey de Grey

De Grey's research focuses on whether regenerative medicine can thwart the aging process. He works on the development of what he calls "Strategies for Engineered Negligible Senescence" (SENS), a tissue-repair strategy intended to rejuvenate the human body and allow an indefinite lifespan. To this end, he has identified seven types of molecular and cellular damage caused by essential metabolic processes. SENS is a proposed panel of therapies designed to repair this damage. An article about SENS published in the viewpoint section of EMBO Reports by 28 scientists concluded that none of de Grey's therapies "has ever been shown to extend the lifespan of any organism, let alone humans".  The SENS Foundation, of which de Grey was a co-founder, seems to agree with the EMBO Report as it states, "If you want to reverse the damage of aging right now I'm afraid the simple answer is, you can't."   Nonetheless, De Grey argues that this reveals a serious gap in understanding between basic scientists and technologists and between biologists studying aging and those studying regenerative medicine.  The 15-member Research Advisory Board of his own SENS Foundation have signed an endorsement of the plausibility of the SENS approach. De Grey is a fellow of the Gerontological Society of America, the American Aging Association, the Institute for Ethics and Emerging Technologies, and an adviser to the Singularity Institute.  He has been interviewed in recent years in a number of news sources, including CBS 60 Minutes, the BBC, The New York Times, Fortune Magazine, The Washington Post, TED, Popular Science, The Colbert Report, Time, and the Skeptics' Guide to the Universe.